A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Public ClinicalTrials.gov record NCT03017820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
Study identification
- NCT ID
- NCT03017820
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 127 participants
Conditions and interventions
Conditions
- B-Cell Non-Hodgkin Lymphoma
- Histiocytic and Dendritic Cell Neoplasm
- Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Anaplastic Large Cell Lymphoma
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- Recurrent Mycosis Fungoides
- Recurrent Plasma Cell Myeloma
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Recurrent T-Cell Non-Hodgkin Lymphoma
- Refractory Acute Myeloid Leukemia
- Refractory Anaplastic Large Cell Lymphoma
- Refractory Angioimmunoblastic T-Cell Lymphoma
- Refractory Mycosis Fungoides
- Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Refractory Plasma Cell Myeloma
- Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
- Biopsy Procedure Procedure
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Cemiplimab Biological
- Computed Tomography Procedure
- Cyclophosphamide Drug
- Echocardiography Test Procedure
- Multigated Acquisition Scan Procedure
- Nivolumab Biological
- Positron Emission Tomography Procedure
- Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter Biological
- Ruxolitinib Drug
- Single Photon Emission Computed Tomography Procedure
- ipilimumab Biological
Procedure · Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 3, 2017
- Primary completion
- Dec 30, 2028
- Completion
- Mar 31, 2032
- Last update posted
- Apr 12, 2026
2017 – 2032
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | Recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03017820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03017820 live on ClinicalTrials.gov.